Trial Profile
PROTECT - Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROTECT
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.